Butidrine
Chemical compound
From Wikipedia, the free encyclopedia
Butidrine (INN), sold under the brand names Betabloc, Butidrate, and Recetan among others, is a beta blocker (or β-adrenergic receptor antagonist) related to pronethalol[1] and propranolol[2] that was developed in the 1960s.[3][4] It is not cardioselective (i.e., is not selective for the β1-adrenergic receptor over the β2-adrenergic receptor).[5] It has membrane stabilizing activity but no intrinsic sympathomimetic activity (i.e., partial agonist activity).[6] Similarly to certain other beta blockers, butidrine additionally possesses local anesthetic properties.[7]
Trade namesBetabloc, Butidrate, Recetan
Other namesButedrine; Butydrine; Hydrobutamine; Idrobutamine
| |
| Clinical data | |
|---|---|
| Trade names | Betabloc, Butidrate, Recetan |
| Other names | Butedrine; Butydrine; Hydrobutamine; Idrobutamine |
| Drug class | Beta blocker |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C16H25NO |
| Molar mass | 247.382 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
